3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
8
Phase 2
4
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Colorectal Cancer Metastatic
3
Neoplasm Metastasis
2
Uveal Melanoma
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Neurofibromatosis 2
1
Neoplasms
1
Macular Degeneration
1
Lung Neoplasms
1
Colorectal Neoplasms
1
Carcinoma
1
Interventions
Paclitaxel
20
Gemcitabine
16
Dexamethasone
16
Bevacizumab
16
Docetaxel
15
Oxaliplatin
14
Cyclophosphamide
13
Carboplatin
12
Capecitabine
12
Sorafenib
11
Fluorouracil
11
Leucovorin
10
Cisplatin
10
pembrolizumab
9
Pemetrexed
9
Epoetin Alfa
9
venetoclax
8
Prednisone
8
Fentanyl
8
Drug Therapy
8
Doxorubicin
8
atezolizumab
7
Rivaroxaban
7
Rituximab
7
Darbepoetin alfa
7
Anastrozole
7
Panitumumab
6
Ondansetron
6
Morphine
6
Irinotecan
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Neoplasms
×
aflibercept
×
Clear all
NCT00519285
2016-07-22
VENICE
Sanofi
Phase 3
Completed
1,224 enrolled
21 charts